Evidence map›Paper›PMID 35292878›Full record

ReviewThe AAPS journal2022

Nanotechnology-Driven Cell-Based Therapies in Regenerative Medicine.

D Alzate-Correa, W R Lawrence, A Salazar-Puerta, N Higuita-Castro, D Gallego-Perez

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The AAPS journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Nanomaterials for biomedical applications.Beilstein journal of nanotechnology · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

D Alzate-Correa *Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio, 43210, USA.
W R Lawrence *Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio, 43210, USA.
A Salazar-PuertaDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, 43210, USA.
N Higuita-CastroDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, 43210, USA.
D Gallego-PerezDepartment of Biomedical Engineering, The Ohio State University, Columbus, Ohio, 43210, USA. gallegoperez.1@osu.edu.

Funding

Novel nanoscale approaches to whole tissue reprogrammingDP2EB028110 · NIBIB · OHIO STATE UNIVERSITY · PI GALLEGO-PEREZ, DANIEL · 2018 to 2022
$2.7M
Non-Viral Modulation of Cutaneous Tissue Plasticity as a Therapy for DiabetesDP1DK126199 · NIDDK · OHIO STATE UNIVERSITY · PI GALLEGO-PEREZ, DANIEL · 2020 to 2020
$737k
NIBIB NIH HHS DP2 EB028110NIDDK NIH HHS DP1 DK126199
6 · The paper itself

Abstract

The administration of cells as therapeutic agents has emerged as a novel approach to complement the use of small molecule drugs and other biologics for the treatment of numerous conditions. Although the use of cells for structural and/or functional tissue repair and regeneration provides new avenues to address increasingly complex disease processes, it also faces numerous challenges related to efficacy, safety, and translational potential. Recent advances in nanotechnology-driven cell therapies have the potential to overcome many of these issues through precise modulation of cellular behavior. Here, we describe several approaches that illustrate the use of different nanotechnologies for the optimization of cell therapies and discuss some of the obstacles that need to be overcome to allow for the widespread implementation of nanotechnology-based cell therapies in regenerative medicine.

Indexed as

NanotechnologyRegenerative MedicineCell- and Tissue-Based Therapydirect cell reprogrammingnanotechnologynanotransfectionregenerative medicinestem cell therapy

Identifiers

PMID35292878
PMCPMC9074705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.